Camp4 Therapeutics Corp
No enriched coverage for $CAMP in the last 7 days.
Schwab Andrew J. sold 191,865 indirectly-held shares of Camp4 Therapeutics Corp (CAMP) at an average of $4.59 ($4.50–$4.76, $0.88M total) across 3 trades over 2026-08-19 to 2026-08-21.
Polaris-affiliated funds and individuals updated their ownership in Camp4 Therapeutics (CAMP) common stock, reporting a lower percentage due to dilution from new share sales. Polaris Management Co. VII now owns 4.8% (3,023,161 shares), while board member Amir Nashat owns 6.3% (3,932,251 shares). The amendment reflects changes since the prior filing.
CAMP4 Therapeutics (CAMP) reported Q2 2026 net loss of $33.5M, or $0.58/share, versus $12.6M, or $0.62/share, a year earlier. The wider loss was mainly due to a $20.9M non-cash derivative fair value change. R&D rose to $10.8M. CAMP4 received Australia and Argentina clearance for a Phase 1/2 CMP-002 trial, expected to start in Q4 2026, and raised $50.1M, extending runway to end-2028.
Recent CAMP coverage spans insider activity, earnings and financial news.
In the last 30 days, CAMP insiders filed 9 SEC Form 4 transactions — 4 purchases ($59K) and 5 sales ($888K). The most active reporter was Schwab Andrew J. with 4 filings.
Insider sale may signal lack of confidence or liquidity need, potentially pressuring the stock.
The dilution reduces Polaris’s influence, potentially pressuring CAMP stock lower.
Regulatory clearances plus a planned Phase 1/2 start window and a fresh $50.1M cash raise are near-term catalysts for CAMP’s clinical and financing risk profile.
Near-term catalyst is regulatory clearance plus planned Q4 2026 trial initiation, supported by an extended cash runway to end-2028.
The filing is a modest insider open-market purchase that may be read as confidence, but it is unlikely to be a standalone driver of fundamentals.
alphai scores every news story that mentions CAMP with an AI model for sentiment and relevance, and aggregates insider trades from Camp4 Therapeutics Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Schwab Andrew J. sold 191,865 indirectly-held shares of Camp4 Therapeutics Corp (CAMP) at an average of $4.59 ($4.50–$4.76, $0.88M total) across 3 trades over 2026-08-19 to 2026-08-21.
1 min readPolaris-affiliated funds and individuals updated their ownership in Camp4 Therapeutics (CAMP) common stock, reporting a lower percentage due to dilution from new share sales. Polaris Management Co. VII now owns 4.8% (3,023,161 shares), while board member Amir Nashat owns 6.3% (3,932,251 shares). The amendment reflects changes since the prior filing.
2 min readCAMP4 Therapeutics (CAMP) reported Q2 2026 net loss of $33.5M, or $0.58/share, versus $12.6M, or $0.62/share, a year earlier. The wider loss was mainly due to a $20.9M non-cash derivative fair value change. R&D rose to $10.8M. CAMP4 received Australia and Argentina clearance for a Phase 1/2 CMP-002 trial, expected to start in Q4 2026, and raised $50.1M, extending runway to end-2028.
4 min readCamp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Results of Operations and Financial Condition. CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth qua
4 min readYoung Richard A purchased 16,378 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
2 min readMaricich Yuri (Chief Medical Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
2 min readGold Kelly (Chief Financial Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
1 min readMandel-Brehm Josh (Chief Executive Officer) purchased 6,551 shares of Camp4 Therapeutics Corp (CAMP) at $1.65 on 2026-08-03.
2 min readCamp4 Therapeutics Corp (CAMP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement Proceeds of $50.1 million will be used to support the Company’s advancement of CMP-002 for the treatment of SYNGAP1-related disorder CAMBRIDGE, Mass., August 04, 2026 (GLOBE NEWSWIRE) -- CA
4 min readBiotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI
3 min read